Our therapeutic proteins

THOR-707 Not Alpha IL-2

THOR-707 as a Single Agent

THOR-707 is a variant of recombinant human IL-2 that is pegylated at one specific site, designed to block engagement of the high affinity IL-2 receptor α chain, extend half-life by slowing THOR-707’s clearance from the body, increase tumor distribution and retention, and improve solubility and uniformity of molecule mass, or monodispersity. We have designed THOR-707 to kill tumor cells by increasing CD8+ T and NK cells without causing VLS, which has been observed with aldesleukin, an IL-2 therapeutic that was approved by the FDA over 25 years ago for the treatment of patients with metastatic renal cell carcinoma and metastatic melanoma. Durable clinical responses and in some cases, cures, have been observed in these patients following treatment with aldesleukin due to increases in CD8+ T cells, which are a subset of T cells that identify and destroy tumor cells. However, widespread use of aldesleukin has been limited by toxicities, which include life-threatening and sometimes fatal VLS as well as by its short half-life, requiring dosing three times per day over eight days.

THOR-707 was designed to have key advantages over current IL-2 therapies, such as improved selectivity, increased therapeutic index, ease of use and reduced risk for anti-drug antibodies.

THOR-707 in Combination with Checkpoint Inhibitor(s)

Published preclinical literature shows that combining IL-2 treatment with PD-1 inhibitors could have synergistic effects in enhancing CD8+ T cell responses. As a result, we believe that THOR-707 in combination with immune checkpoint inhibitors may have greater anti-tumor effects than PD-1 inhibitors alone without the VLS observed with aldesleukin.

We plan to file an IND with the FDA in the second quarter of 2019 and, thereafter, initiate a Phase 1/2 clinical trial of THOR-707 in multiple tumor types as both a single agent and in combination with immune checkpoint inhibitors.

IL-2 Synthorin for Autoimmune Indications

Our second IL-2 program is focused on autoimmune disorders based on the observation that low doses of IL-2 can dampen immune cell activation. However, the short half-life of low dose IL-2 renders its administration
impractical for the treatment of chronic autoimmune disorders. We are developing an IL-2 autoimmune, or AI, Synthorin designed to overcome this limitation. We have identified multiple potential product candidates fordevelopment and intend to nominate a lead IL-2 AI Synthorin product candidate in 2019, and start IND-enabling studies thereafter. We plan to develop our IL-2 AI Synthorin initially in chronic graft versus host disease, or GVHD, atopic dermatitis and Crohn’s disease and will determine which specific indications we will target with IL-2 after completing our initial clinical trials.

Other Cytokine Programs


IL-10 is an immune cell growth factor in humans that is critical for the proliferation and activity of tumor killing immune cells. We are using our Expanded Genetic Alphabet platform technology to develop an IL-10 Synthorin with extended half-life and improved pharmacokinetics that could not be manufactured with conventional techniques. We expect to begin in vitro and in vivo studies of our Synthorin IL-10 in the first half of 2019 and begin IND-enabling studies thereafter.


IL-15 is another immunoregulatory cytokine with a well-established role in the anti-tumor immune response. We are using our Expanded Genetic Alphabet platform technology to design and develop IL-15 Synthorins with differentiated properties by site-specific pegylation. We have discovered multiple molecules and expect to identify a development candidate in the first half of 2019.